News >

High Response Rate, MRD Negativity Confirmed for Venetoclax in CLL

Published: Friday, Sep 22, 2017

Dr. William G. Wierda

William G. Wierda, MD, PhD
Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia (CLL), an updated analysis of a pivotal clinical trial showed.

The most frequent serious AEs were pneumonia (10%), autoimmune hemolytic anemia (5%), and pyrexia (5%). Wierda reported that 81% of patients developed infections (all grades), including 23% that were grade 3/4. The rate and spectrum of infections were consistent with the underlying disease, he said.
Wierda W, Chyla B, Eichhorst B, et al. Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease (MRD) from the full population of the pivotal M13-982 trial.  Presented at 2017 SOHO Annual Meeting. Abstract CLL-102.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication